SecSonar.com

Lyell Immunopharma, Inc. (LYEL)

Lyell Immunopharma, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Lyell Immunopharma, Inc. (LYEL) is a Biotechnology company based in US with a market capitalization of $406.2M. Revenue declined 41.0% year-over-year and free cash flow was negative at -$150.8M. This page tracks LYEL's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 300 employees · IPO Jun 17, 2021

Valuation

Valuation & price

$17.92 · as of May 17, 2026 · -53.6% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

1.64

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$38.60$23.85$9.10Jul 25Dec 25Jul 26Jul 7, 25$9.15Jul 9, 25$10.21Jul 11, 25$9.75Jul 15, 25$9.10Jul 17, 25$9.52Jul 21, 25$9.49Jul 23, 25$10.99Jul 25, 25$12.42Jul 29, 25$12.87Jul 31, 25$11.81Aug 4, 25$11.37Aug 6, 25$11.08Aug 11, 25$10.58Aug 13, 25$10.83Aug 15, 25$10.58Aug 19, 25$10.83Aug 21, 25$10.65Aug 25, 25$10.97Aug 27, 25$11.28Aug 29, 25$11.08Sep 3, 25$11.43Sep 5, 25$12.15Sep 9, 25$13.15Sep 11, 25$13.30Sep 16, 25$13.22Sep 18, 25$12.64Sep 22, 25$13.17Sep 24, 25$13.45Sep 26, 25$12.83Sep 30, 25$16.24Oct 2, 25$15.81Oct 6, 25$17.85Oct 8, 25$18.26Oct 10, 25$16.51Oct 14, 25$16.86Oct 16, 25$17.00Oct 21, 25$17.32Oct 23, 25$18.32Oct 27, 25$17.23Oct 29, 25$16.59Oct 31, 25$16.66Nov 4, 25$15.95Nov 6, 25$17.88Nov 10, 25$17.68Nov 12, 25$17.63Nov 14, 25$16.93Nov 18, 25$17.93Nov 20, 25$17.43Nov 25, 25$22.53Nov 28, 25$24.00Dec 2, 25$20.81Dec 4, 25$25.46Dec 8, 25$28.36Dec 10, 25$31.28Dec 12, 25$34.46Dec 16, 25$32.64Dec 18, 25$32.38Dec 22, 25$37.37Dec 24, 25$38.60Dec 29, 25$36.05Jan 2, 26$28.98Jan 6, 26$25.73Jan 8, 26$24.30Jan 12, 26$23.77Jan 14, 26$23.46Jan 16, 26$23.76Jan 21, 26$24.12Jan 23, 26$25.26Jan 27, 26$25.28Jan 29, 26$24.81Feb 2, 26$24.77Feb 4, 26$24.18Feb 9, 26$23.25Feb 11, 26$24.34Feb 13, 26$25.84Feb 18, 26$24.39Feb 20, 26$21.40Feb 24, 26$23.07Feb 26, 26$23.01Mar 2, 26$24.10Mar 4, 26$23.80Mar 6, 26$22.46Mar 10, 26$25.63Mar 12, 26$24.78Mar 17, 26$20.14Mar 19, 26$20.77Mar 23, 26$19.55Mar 25, 26$20.14Mar 27, 26$19.67Mar 31, 26$20.06Apr 2, 26$21.21Apr 7, 26$21.78Apr 9, 26$23.85Apr 13, 26$24.80Apr 15, 26$23.84Apr 17, 26$24.01Apr 22, 26$24.78Apr 24, 26$22.41Apr 28, 26$21.49Apr 30, 26$19.73May 4, 26$20.72May 6, 26$20.85May 8, 26$19.33May 12, 26$19.25May 14, 26$19.02May 18, 26$16.51May 20, 26$17.22May 22, 26$17.46May 28, 26$16.83Jun 1, 26$17.15Jun 3, 26$12.57Jun 5, 26$11.97Jun 9, 26$12.70Jun 11, 26$13.72Jun 15, 26$13.55Jun 17, 26$12.52Jun 22, 26$11.97Jun 24, 26$13.00Jun 26, 26$11.61Jul 2, 26$14.05
$9.1052-week range$38.60
Loading valuation history…

Fundamentals

Key fundamentals

$406.2M

Market cap

-41.0%

Revenue growth (YoY)

-31952.8%

Gross margin

-$150.8M

Free cash flow (USD)

-$205.3M

Net debt

Net cash position

30.7%

Share dilution

2/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2019 → 2025

FY 2019$657.0KFY 2020$7.8MFY 2021$10.7MFY 2022$84.7MFY 2023$130.0KFY 2024$61.0KFY 2025$36.0K
$657K$36K

Free cash flow by year

2019 → 2025

FY 2019$23.4MFY 2020$-212.4MFY 2021$-191.8MFY 2022$-193.8MFY 2023$-166.4MFY 2024$-162.9MFY 2025$-150.8M
$23.4M-$150.8M

Gross margin by year

2021 → 2025

FY 2021100.0%FY 2022100.0%FY 2023100.0%FY 2024100.0%FY 2025-31952.8%
100.0%-31952.8%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

5

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 6, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Insider sellInsider Sell $4KBulis Veronica Sanchez · VP, Corporate Controller · $4.1KJun 15, 2026Filing
  • Insider sellInsider Sell $2KHill Stephen J. · Chief Operating Officer · $1.7KJun 15, 2026Filing
  • Insider sellInsider Sell $2KLee Gary K. · Chief Scientific Officer · $2.5KJun 15, 2026Filing
  • Insider sellInsider Sell $7KSeely Lynn · Director, President and CEO · $7.3KJun 15, 2026Filing
  • 8-K eventAnnual Meeting ResultsJun 15, 2026Filing
  • Insider sellInsider Sell $25KShook David · Chief Medical Officer · $25KJun 11, 2026Filing
  • 8-K eventEarnings ReleaseMay 6, 2026Filing
  • Quarterly report10-Q FiledMay 6, 2026Filing
  • FinancingSecurities RegistrationApr 3, 2026Filing

Questions

Frequently asked questions

What is Lyell Immunopharma, Inc.'s market cap?

Lyell Immunopharma, Inc. (LYEL) has a market capitalization of $406.2M.

What is LYEL's P/E ratio?

A meaningful P/E ratio is not available for LYEL — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is LYEL's price-to-book (P/B) ratio?

LYEL trades at 1.64 times book value per share.

Are insiders buying LYEL stock?

SEC Form 4 filings show no open-market insider buys at Lyell Immunopharma, Inc. in the last 90 days (5 sells).

Same arena

Related companies in Biotechnology

XFOR

X4 Pharmaceuticals, Inc.

$402.3M

VNDA

Vanda Pharmaceuticals Inc.

$391.5M

ADCT

ADC Therapeutics S.A.

$433.1M

FULC

Fulcrum Therapeutics, Inc.

$377.7M

PRTC

PureTech Health plc

$439.4M

NGNE

Neurogene Inc.

$441.4M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.